Literature DB >> 5666107

Aerogenic BCG vaccination against tuberculosis in animal and human subjects.

S R Rosenthal, J T McEnery, N Raisys.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5666107     DOI： 10.3109/02770906809100348

Source DB:  PubMed          Journal:  J Asthma Res        ISSN： 0021-9134


× No keyword cloud information.
  18 in total

1.  Immunization by a bacterial aerosol.

Authors:  Lucila Garcia-Contreras; Yun-Ling Wong; Pavan Muttil; Danielle Padilla; Jerry Sadoff; Jessica Derousse; Willem Andreas Germishuizen; Sunali Goonesekera; Katharina Elbert; Barry R Bloom; Rich Miller; P Bernard Fourie; Anthony Hickey; David Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-14       Impact factor: 11.205

2.  Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

Authors:  Nacho Aguilo; Ana Maria Toledo; Eva Maria Lopez-Roman; Esther Perez-Herran; Eamonn Gormley; Joaquin Rullas-Trincado; Iñigo Angulo-Barturen; Carlos Martin
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

3.  Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice.

Authors:  Steven C Derrick; Kristopher Kolibab; Amy Yang; Sheldon L Morris
Journal:  Clin Vaccine Immunol       Date:  2014-08-20

4.  Systemic and mucosal immune responses after intranasal administration of recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing glutathione S-transferase from Schistosoma haematobium.

Authors:  L Kremer; L Dupré; G Riveau; A Capron; C Locht
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG.

Authors:  E L Nuermberger; T Yoshimatsu; S Tyagi; W R Bishai; J H Grosset
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 6.  Harnessing local and systemic immunity for vaccines against tuberculosis.

Authors:  P C L Beverley; S Sridhar; A Lalvani; E Z Tchilian
Journal:  Mucosal Immunol       Date:  2013-11-20       Impact factor: 7.313

Review 7.  Pharmaceutical aerosols for the treatment and prevention of tuberculosis.

Authors:  Shumaila N M Hanif; Lucila Garcia-Contreras
Journal:  Front Cell Infect Microbiol       Date:  2012-09-07       Impact factor: 5.293

8.  Simultaneous immunization against tuberculosis.

Authors:  Elma Z Tchilian; Edward O Ronan; Catherine de Lara; Lian Ni Lee; Kees L M C Franken; Martin H Vordermeier; Tom H M Ottenhoff; Peter C L Beverley
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

Review 9.  Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool.

Authors:  Christopher L Karp; Christopher B Wilson; Lynda M Stuart
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

10.  Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

Authors:  Iman Satti; Joel Meyer; Stephanie A Harris; Zita-Rose Manjaly Thomas; Kristin Griffiths; Richard D Antrobus; Rosalind Rowland; Raquel Lopez Ramon; Mary Smith; Sharon Sheehan; Henry Bettinson; Helen McShane
Journal:  Lancet Infect Dis       Date:  2014-08-20       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.